Exit at AMW GmbH
AMW GmbH, a specialty pharmaceutical company focusing on biodegradable drug delivery systems, has announced a change in its shareholder structure. The new majority shareholders are the investment company Ren Life Sciences and Juno Capital Partners, an international investor based in Toronto.
The new shareholders take over the holdings of the previous investors Bayern Kapital, BayBG, KfW, UVC Partners and bmp Ventures with the IBG funds.
Two investors remain involved
Even after the change of ownership, two previous shareholders will remain invested: SHS Capital, an investor specializing in fast-growing healthcare companies, and AMW Evolution, a special purpose vehicle representing the Chairman of the Advisory Board, CEO, members of management and employees of the company, among others.
The collaboration with Ren Life Sciences and Juno Capital Partners, as well as the continuation of the partnership with SHS Capital, is the perfect set-up to secure our long-term growth
Philipp Karbach, CEO and shareholder AMW
SHS Capital was already one of AMW's first investors and has reinvested via a current fund as part of the new structure.
Record turnover in 2025
Parallel to the entry of the new investors, the company once again recorded record sales in the 2025 financial year. CEO Philipp Karbach sees this as a solid basis for the next phase of growth.
With the new partners, the company intends to further expand its position and take on a leading role in the development, production and marketing of biodegradable systems for controlled drug delivery in the long term.
Martin Zügel, Chairman of the Advisory Board, emphasizes that Ren Life Sciences and Juno Capital Partners are international growth capital providers with experience in building up global pharmaceutical companies.
Innovative drug delivery technologies
AMW GmbH develops and produces biodegradable implants that release drugs in the body over a longer period of time in a controlled manner. The aim is to improve treatment adherence and at the same time enable cost-effective treatments.
The company covers the entire value chain - from co-development to production and international marketing.
The approved products include implants that release the active ingredients goserelin or leuprorelin. In Germany, leuprorelin is marketed under the trade name Leugon by the wholly-owned subsidiary Endomedica GmbH.
In addition, AMW works with pharmaceutical and biotech companies worldwide to develop new drug products and produce them along the entire product life cycle. The company's headquarters are located in Warngau in the greater Munich area.
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
